CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T CellsMatthias Braun, Tobias Bald, Amelia Roman Aguilera et al.|Immunity|2020Cited by 181
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis Paz‐Ares, C. Chouaïd, Óscar Juan et al.|Journal of Clinical Oncology|2024Cited by 126
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Mark J. Smyth, Jason Madore et al.|Clinical Cancer Research|2020Cited by 113
Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replicationWen Juan Tu, Sudha Rao, Robert McCuaig et al.|Cell Discovery|2021Cited by 20
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancerAmy Body, Eva Segelov, Luxi Lal et al.|Vaccine|2024Cited by 15